Mercury Bio
SANTA FE, NM, United States · Biotechnology, Therapeutics · 13 employees
Mercury Bio was formerly known as Spartina Biotechnologies, Inc. Mercury Bio is developing a next-generation biomolecular drug delivery platform. Using a novel system for drug encapsulation in natural vesicles, their technology enhances drug efficacy while reducing side effects through cell-specific targeting. The result is an advanced drug delivery system with a scalable, low-cost production plat
Funding history
- Funding Round — $2.4M — Oct 2025
- Series pre-seed — $3K — Feb 2025
- Series pre-seed — $150K — Apr 2024
- Series seed — $2.0M — Aug 2023
- Series seed — $1.2M — Feb 2023
Recent signals
- Dec 19, 2025: Mercury Bio and Meta-Flux Form Strategic Partnership to Enhance Therapeutics for Parkinson's and Alzheimer's Diseases.
- Dec 09, 2025: Mercury Bio Appoints Cassandra 'Casey' Perkins as Vice President of Corporate Strategy & Business Development
- Oct 24, 2025: Raised $2.4M
- Feb 21, 2025: Raised $3K in Series pre-seed
- Apr 03, 2024: Raised $150K in Series pre-seed
- Aug 30, 2023: Raised $2.0M in Series seed
- Feb 17, 2023: Raised $1.2M in Series seed
- Nov 14, 2022: Raised $200K
See plans & pricing → Track Mercury Bio’s funding, hiring, and signals — with verified contacts — on Fundz.